Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Acquires $216,402.40 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 24,760 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $8.74 per share, for a total transaction of $216,402.40. Following the transaction, the director owned 17,697,436 shares in the company, valued at $154,675,590.64. The trade was a 0.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The stock was bought at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han purchased 210,000 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.

Burning Rock Biotech Trading Up 7.0%

BNR stock opened at $8.96 on Thursday. Burning Rock Biotech Limited Sponsored ADR has a 52-week low of $3.22 and a 52-week high of $41.72. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06. The firm has a market cap of $94.26 million, a P/E ratio of -10.93 and a beta of 1.33. The company’s 50-day simple moving average is $12.79 and its 200-day simple moving average is $20.08.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Institutional Investors Weigh In On Burning Rock Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in shares of Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares during the period. Prospera Financial Services Inc lifted its stake in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares in the last quarter. Marshall Wace LLP acquired a new position in Burning Rock Biotech during the fourth quarter worth $220,000. Finally, Crcm LP boosted its position in shares of Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the period. 30.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.